HDAC6 and melanoma: By packaging the HDAC6 inhibitor NextA along with ICG into PLGA nanoparticles, we aimed to leverage the advantages of NextA for melanoma while mitigating some of the aforementioned limitations observed with PTT and epigenetic therapy as single therapies.